| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2007, p. 3511-3520, Vol. 27, No. 9
0270-7306/07/$08.00+0 doi:10.1128/MCB.01448-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Departments of Cancer Biology,1 Cell Biology, The Lerner Research Institute,4 Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195,2 School of Biomedical Sciences, Kent State University, Kent, Ohio 442403
Received 4 August 2006/ Returned for modification 1 September 2006/ Accepted 13 February 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The deregulation of cellular proliferation, together with defects in apoptosis control, are critical for tumor formation (13). Cyclins, in association with their catalytic subunits, the cyclin-dependent kinases, control cell cycle progression by regulating events that drive the transition between cell cycle phases (12, 33, 39). The cyclin E/Cdk2 complex plays an essential and rate-limiting role in the transition between the G1 and S phases of the cell cycle (36, 40) and in the initiation of DNA replication (22, 36). In addition to its role in cell cycle control (11, 25, 36, 40), cyclin E has been shown to have an important function in genotoxic stress-induced apoptosis of tumor cells of hematopoietic origin (30, 31). Cyclin E levels are upregulated by genotoxic stress, and increased cyclin E expression sensitizes cells to apoptotic stimuli (32). Moreover, during apoptosis, cyclin E is proteolytically cleaved to generate a C-terminal p18-cyclin E fragment. Unlike full-length cyclin E, p18-cyclin E cannot interact with Cdk2, suggesting that its apoptotic function is independent of the cyclin E/Cdk2 complex and its associated kinase activity (30).
The major pathway dedicated to the repair of DNA double-strand breaks in mammalian cells is that of nonhomologous end joining (NHEJ) mediated by the Ku70/Ku80 heterodimer, referred to as Ku (29). The nuclear pool of Ku70 is essential for the repair DNA double-strand breaks in vivo as it provides the DNA binding component required for activating the DNA-dependent protein kinase, which is one of the main functions of Ku (23). However, Ku is a relatively abundant protein that is present in both the cytosol and the nucleus (14). Deregulated Ku70 expression has been reported in a number of cancer cell lines (28). Decreased Ku70 levels can increase cellular sensitivity to stresses that trigger the mitochondrial apoptotic pathway. For example, it was reported that Ku70-deficient cells display increased sensitivity to ionizing radiation (18, 28). Ku70 can also function as a physiological cytoprotector by binding Bax and sequestering it in the cytosol, thereby preventing Bax activation and subsequent apoptosis (4, 44).
In this study, we identify Ku70 as the critical interacting partner of p18-cyclin E. As a result of this interaction, Bax dissociates from Ku70 in hematopoietic cells that are undergoing apoptosis following genotoxic stress or in cells where p18-cyclin E is expressed ectopically. These findings identify a novel mechanism of amplification of cell death through a key step in Bax activation that is critical for apoptosis induced by genotoxic stress.
(This work has been presented partly at the CSHL Meeting on Programmed Cell Death [September 2005] and the International Symposium on the Mechanism of Cell Death [June 2006].)
| MATERIALS AND METHODS |
|---|
|
|
|---|
Transfection studies. Cells were transiently transfected with various Ku70 or cyclin E constructs using Lipofectamine (Invitrogen) as described previously (30). Bax knockdown was achieved in IM-9 cells using siLentFect lipid reagent (Bio-Rad) and siBax oligonucleotides (siGENOME SMART pool; Dharmacon) as described previously (38).
Western blot and immunoprecipitation analysis. For immunoblots, cells were lysed in a buffer consisting of 20 mM HEPES, pH 7.5, 1 mM EDTA, 150 mM NaCl, 1% NP-40, 1 mM dithiothreitol, and protease inhibitors and immunoblotting was performed with antihemagglutinin (anti-HA) (1:1,000), anti-His (1:500; Covance, Berkeley, CA), anti-Flag (1:500; Sigma), anti-Bax (6A7) (1:1,000; Pharmingen, San Diego, CA), anti-poly(ADP-ribose) polymerase 1 (anti-PARP-1) (1:1,000), anti-active caspase-3 (1:1,000; Cell Signaling, Beverly, MA), anti-ß-actin (1:2,000; Sigma), anti-Ku70 (1:250), and anti-Ku80 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. For immunoprecipitation, the lysis buffer composition was similar to that employed for Western blots except that 0.05% NP-40 was used instead of 1%. Bax immunoprecipitation was performed with a polyclonal antibody to Bax (Santa Cruz) in 1% CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} buffer containing freshly added protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and leupeptin). Precleared cell lysates (500 µg) were incubated with 0.5 µg antibody for 2 h at 4°C, followed by incubation with protein A plus G agarose beads for 1 h at 4°C. Beads were washed with lysis buffer and boiled with 2x sample buffer. The eluted proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and Western blotting was performed using the appropriate antibodies, as described previously (30).
Apoptosis assays. Apoptosis was determined by examining the generation of active caspase-3, active Bax, and the 85-kDa PARP-1-derived proteolytic fragment in Western blot studies with antibodies for active caspase-3, active Bax (6A7), and PARP-1. In some experiments, the loss of cell viability was directly assessed by trypan blue exclusion by light microscopy. Two hundred cells were counted for each experiment. Each experimental data point, indicating the percentage of cells undergoing apoptosis, represents the mean ± standard error of the mean (SEM) of results from two experiments. Caspase assays were performed for colorimetric detection (405-nm absorbance) by using VDVAD-pNA, DEVD-pNA, and LEHD-pNA as substrates for caspase-2, -3, and -9, respectively, as described previously (3, 17).
Yeast two-hybrid screening.
p18-cyclin E (as bait) was subcloned following the GAL4 DNA binding domain of the pGBKT7 vector containing a c-Myc epitope tag (MATCHMAKER two-hybrid system 3; Clontech, CA). The K562 hematopoietic cell cDNA library was cloned following the GAL4 DNA activation domain of the pACT2 vector (HA epitope tag). When bait and library fusion proteins interact, transcriptional activation of the reporter genes is expected. The Saccharomyces cerevisiae AH109 yeast strain containing the ADE2 and HIS3 markers was cotransformed with the DNA binding domain (bait) and the activation domain (fusion library) (at a titer of
2 x 106 CFU) containing the TRP1 and LEU2 selection markers, respectively. Yeast growth, selection, and screening were performed following the manufacturer's instructions (MATCHMAKER two-hybrid system 3; Clontech, CA).
Mass spectrometry. HEK293T cells were transiently transfected with cyclin E and p18-cyclin E. At 16 h posttransfection, cell lysates were subjected to immunoprecipitation with an anti-HA antibody, as these constructs have an expressed HA tag at the C terminus. The immunoprecipitates were separated by SDS-PAGE, transferred to membrane, and stained with Coomassie blue, and specific bands were analyzed by mass spectrometry. For protein digestion, the bands were cut from the gel as closely as possible to minimize excess polyacrylamide and washed/destained in two aliquots of 50% ethanol-5% acetic acid. The gel pieces were washed in 0.1 M ammonium bicarbonate and dehydrated in acetonitrile before reduction with dithiothreitol and alkylation with iodoacetamide. The gel pieces were then dehydrated in acetonitrile, washed in 0.1 M ammonium bicarbonate, dehydrated, and dried with a Speed-Vac. Gel pieces were rehydrated in 30 µl of trypsin (20 ng/µl) in 50 mM ammonium bicarbonate on ice for 10 min. Any excess trypsin solution was removed, and 20 µl of 50 mM ammonium bicarbonate was added. The sample was digested overnight at room temperature. The peptides that were formed were extracted from the polyacrylamide in two aliquots of 30 µl of 50% acetonitrile-5% formic acid. These extracts were combined and evaporated to <20 µl for liquid chromatography-mass spectrometry analysis (Finnigan LCQ-Deca ion trap mass spectrometer system with a Protana microelectrospray ion source interfaced with a Phenomenex Jupiter C18 reverse-phase capillary chromatography column).
Two-microliter volumes of the extract were injected, and the peptides were eluted from the column by an acetonitrile-0.05 M acetic acid gradient. The digest was analyzed using the data-dependent multitask capability of the instrument acquiring full-scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in successive instrument scans. The data were analyzed by using all collision-induced dissociation spectra collected in the experiment to search the NCBI nonredundant database with the search program TurboSEQUEST. All matching spectra were verified by manual interpretation. The interpretation process was also aided by additional searches using the Mascot and FASTA programs.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
60% by the overexpression of p18-cyclin E (Fig. 4A, lane 2). Cell death, as measured by trypan blue exclusion, was apparent in about 30% of cells following p18-cyclin E expression, confirming that p18-cyclin E can induce cell death when expressed ectopically. Cell death and Bax activation (Fig. 4B and C) caused by p18-cyclin E correlated with a reduction in the Bax/Ku70 association (Fig. 4A). p18-cyclin E-induced loss of cell viability, as well as Bax activation, could be prevented by coexpression of wild-type Ku70 or the Ku70(1-535) but not Ku70(496-609) mutant (Fig. 4B and C). Strikingly, Ku70(496-609) could not reverse Bax activation by p18-cyclin E, leading to diminished association of Ku70 with Bax. This is because once Bax gets activated following its displacement from Ku70 by p18-cyclin E, active Bax can no longer bind to Ku70(496-609) (Fig. 4A and C). However, Ku70(496-609) and wild-type Ku70 can abolish the cell death induced by green fluorescent protein-Bax (see the supplemental material), as the Ku70 domain of 496 to 609 amino acid residues binds to inactive Bax in the cytosol (4). Moreover, we have tested these mutants in cells that do not express p18-cyclin E. The expression of Ku70-derivative mutants alone does not have a significant effect on cell death. From the results of these experiments, we conclude that Bax is present in a complex with Ku70, and a disruption of this complex by p18-cyclin E correlates with increased apoptosis, suggesting that Bax mediates the apoptotic effect of p18-cyclin E although there could be a possibility of Bax-independent cell death induced by p18-cyclin E.
|
|
Cyclin E has a well-known role in cell cycle regulation. However, no interaction was detected between p18-cyclin E and Cdk2 by transfection-based assays, suggesting that p18-cyclin E has no effect on its cyclin E/Cdk2-associated function (30). To directly address whether the functional contribution of p18-cyclin E to apoptosis is indeed independent of the cell cycle regulatory function of cyclin E, p18-cyclin E was expressed in wild-type and cyclin E knockout MEFs. As human and mouse cells express two cyclin E genes, cyclin E1 and cyclin E2, both have been inactivated by homologous recombination to prevent any possible compensatory mechanisms (16). p18-cyclin E induced robust apoptosis as determined by PARP-1 cleavage and the activation of caspase-3 in both wild-type and cyclin E1/E2 knockout MEFs, indicating that the cell death-inducing effect of p18-cyclin E is independent of the well-known cell cycle regulatory function of cyclin E (Fig. 5D). Interestingly, there seems to be less caspase activation in cyclin E+/+than in cyclin E/ cells (Fig. 5D). Nevertheless, cell death mediated by p18-cyclin E takes place even in the absence of cyclin E. This is important as our (32) and other (21) reports indicate that cyclin E/Cdk2 can also participate in cell death, a component that can be ruled out in the present study. There is not only more active caspase-3 but also cleaved PARP-1, the latter likely being attributed to higher levels of constitutive PARP-1 expression in these cells. The reason for more PARP-1 and caspase-3 proteolytic cleavage in cyclin E-deficient cells is unclear.
p18-cyclin E generation in hematopoietic cells is essential for dissociation of Bax from Ku70 and its activation. We next examined the complex formation of Ku70 with Bax in B-cell-derived IM-9 tumor cells. We previously reported that these cells undergo apoptosis when challenged with apoptotic stimuli, such as ionizing radiation or DNA-damaging chemotherapeutic agents (3, 30). A coimmunoprecipitation experiment indicated that Bax associates with Ku70 in IM-9 cells (Fig. 6A). This interaction was diminished at 16 and 24 h after irradiation. The p18-cyclin E that was generated following irradiation (Fig. 6B) associated with Ku70 (Fig. 6C), with most of the endogenous p18-cyclin E being found in this complex. The p18-cyclin E binding to Ku70 coincided with the dissociation of Bax from Ku70 and Bax activation, as determined by its immunoreactivity with the active Bax conformation-specific antibodies (Fig. 6A). These events were preceded by the activation of caspase-3 and the cleavage of its cellular substrates: PARP-1 and cyclin E (Fig. 6B). Although caspase-3 activation and PARP-1 cleavage were apparent at 4 h, there was a minimal fraction of p18-cyclin E present at this time. By 8 h, however, levels of p18-cyclin E became more abundant. Concomitantly, levels of cyclin E decreased dramatically by 24 h as p18-cyclin E levels rose. These data support the idea of a sequential activation of caspases and cleavage of cyclin E to generate p18-cyclin E, which is followed by Bax dissociation from Ku70 and its activation.
|
A well-established molecular mechanism to inhibit Bax-induced apoptosis is through Bcl-2 overexpression (10). We have previously shown that ectopic expression of Bcl-2 in IM-9 cells not only prevents apoptosis (3) but also inhibits the appearance of p18-cyclin E (30). The examination of the Bax/Ku70 association indicates that Bcl-2 expression also precludes any changes in the Bax/Ku70 association, even at 48 h following irradiation (Fig. 6E). This result, taken together with the above data, indicates that when p18-cyclin E genesis is prevented by blocking caspase activation or by Bcl-2 expression, there is no change in the Bax/Ku70 interaction following irradiation. This indicates that the disruption of the Ku70/Bax interaction following irradiation of hematopoietic tumor cells is not a consequence of apoptosis and that the dissociation of Bax from Ku70 requires p18-cyclin E.
Caspase-9 but not caspase-2 is required for p18-cyclin E genesis.
Earlier we showed that the generation of p18-cyclin E is mediated by caspase-3 or a caspase-3-like activity (30). To further delineate which upstream caspase is involved in cyclin E cleavage, IM-9 cells were treated with specific inhibitors of caspase-9, caspase-3, and caspase-2 as well as the broad-spectrum inhibitor (zVAD-fmk) either at the time of irradiation (0 h) or at 8 h following radiation treatment, with cells being examined at 24 h postirradiation. While zVAD-fmk and the caspase-3 and caspase-9 inhibitors were effective (when added at the time of irradiation [0 h]) in preventing cell death (Fig. 7A) and the generation of p18-cyclin E and, as a consequence, decreased cyclin E levels (Fig. 7B), the caspase-2 inhibitor VDVAD-fmk had no effect. The proportion of cells that lost viability following irradiation was
70%, whether or not the caspase-2 inhibitor was present, with less than 5% of cells being nonviable when any of the other three caspase inhibitors were used. However, while the addition of zVAD-fmk and the caspase-3 and caspase-9 inhibitors at 8 h following irradiation still partially blocked the loss of cell viability, it did not have any effect on the generation of p18-cyclin E and the concomitant decrease in cyclin E levels, indicating that cyclin E cleavage is preceding full activation of apoptosis. Consistent with the results with caspase inhibitors, there was very limited caspase-2 activity, with much more robust caspase-9 and caspase-3 activities by 4 h following irradiation. Caspase-2 levels continued to remain minimal, with levels of caspase-9 and -3 activity remaining steady up to 16 h, a time after which all caspases became more active (Fig. 7C). Using lysates from the experiment shown in panel B indicated that the caspase-2 inhibitor VDVAD-fmk was nevertheless effective in blocking most (>70%) of the residual caspase-2 activity with no effect on caspase-9 (data not shown). These data indicate that caspase-9, not caspase-2, is the initiator caspase in the radiation-induced apoptosis of these cells that leads to caspase-3 activation, cyclin E cleavage, and subsequent Bax activation. A schematic model depicts the key pathways for genotoxic stress-induced apoptosis through the activation of caspases-9 and -3, with p18-cyclin E providing an amplification step required for Bax translocation to mitochondria (Fig. 7D).
|
|
| DISCUSSION |
|---|
|
|
|---|
Proteolytic cleavage of cyclin E is critical for its biological function as the expression of a cleavage-resistant cyclin E mutant in hematopoietic cells greatly inhibits genotoxic stress-induced apoptosis (30). In this study, we identify Ku70 as a p18-cyclin E binding partner and examine the role of this interaction in the mechanism of apoptosis. A key regulatory step in the intrinsic cell death pathway is the activation of the proapoptotic molecule Bax (5). Following its activation, Bax integrates into the outer mitochondrial membrane, where it forms pore-like structures by oligomerization, leading to the release of cytochrome c and other death-inducing factors (6, 38, 48). It has been well established that following its exposure to various cytotoxic stimuli, Bax undergoes multiple conformational changes prior to committing cells to dying by permeabilization of their internal membranes, both in mitochondria and the endoplasmic reticulum (43). Although the mechanism of activation of Bax remains unclear, a recent study indicates that Bax is kept inactive in some resistant cells by interacting with cytosolic Ku70 (4). The overexpression of Ku70 prevents Bax-mediated apoptosis, whereas the depletion of Ku70 causes cells to become more sensitive to a variety of apoptotic stimuli. These results demonstrate that in addition to its well-known role in DNA repair, Ku70 is a physiological inhibitor of Bax-induced apoptosis. Interestingly, cells from Ku70 knockout mice are hypersensitive to agents, such as staurosporine, that induce apoptosis in the absence of DNA damage (1). This suggests that Ku70 plays a role in suppressing apoptosis that is independent of its role in DNA repair. Based on these findings, nuclear Ku70 could therefore be considered to be responsible mainly for the repair of DNA damage, whereas the cytosolic pool of Ku70 may be primarily a regulator of Bax activation (4, 44).
We identified Ku70 and characterized its role in regulating Bax-mediated apoptosis in hematopoietic cells that generate p18-cyclin E from cyclin E by limited activation of caspase-3 following genotoxic stress. Bax may be activated at a minimal level by other BH3 proteins to initiate the cell death process. However, by binding to Ku70, p18-cyclin E can cause the dissociation of inactive Bax from Ku70 and its robust activation, thus leading to a feedback amplification loop that further activates apoptosis. Therefore, Ku70 plays a dual role in NHEJ and the regulation of Bax, which in turn may determine the balance between cell survival and death in hematopoietic cells. However, Ku70 may not be the only molecule that sequesters Bax and prevents its activation. Ku70-deficient cells are viable, although somewhat more sensitive to apoptosis, indicating that Bax should be largely inactive even in the absence of its binding to Ku70. This may be explained by the fact that Bax release from Ku70 represents only a first phase in a multistep process required for the activation of Bax. It is also possible that, in addition to Ku70, other mechanisms exist for keeping Bax sequestered and inactive, for example, through its binding to the humanin protein (19, 51).
Our data reveal a novel mechanism of apoptosis by which the proteolytic cleavage of cyclin E regulates the subsequent amplification stage of the intrinsic pathway of apoptosis. Earlier we showed that cyclin E is cleaved by activated caspase-3 to generate p18-cyclin E (30). The cleavage of cyclin E as well as cell death can be prevented by Bcl-2 overexpression (30), indicating that the function of Bcl-2 is upstream of the activation of the mitochondrial apoptotic cascade and cyclin E cleavage. Here, we show that interaction of p18-cyclin E with Ku70, resulting in the liberation of Bax from the Ku70-Bax complex, has an important function in the amplification stage of apoptosis in hematopoietic cells by initiating a robust activation of Bax, which sustains a feedback loop targeting mitochondria (Fig. 7D). These data are consistent with the feedback amplification loop model we have proposed earlier for these cells to link caspase activation to mitochondrial dysfunction in genotoxic stress-induced apoptosis. We have shown that an initial limited, early caspase activation was not sufficient to release enough cytochrome c to lead to significant apoptosis in hematopoietic cells (3). We have now determined that caspase-9, not caspase-2, was involved in the caspase-3 activation that was responsible for the proteolytic cleavage of cyclin E. Previously we have also shown that caspase-8 and -6 inhibition had no effect on p18-cyclin E generation (30).
Recent findings have suggested that caspase-2 can be an apical regulator in apoptotic pathways leading from DNA damage to the release of mitochondrial cytochrome c and subsequent activation of effector caspases. However, a recent report found that caspase-2 activation-mediated apoptosis was observed only in cells with functional p53 (46), consistent with the mechanisms of its activation that involve the p53-dependent formation of the PIDDosome (45). However, p18-cyclin E generation (e.g., in U266 [26]) and apoptotic function (e.g., in H1299 cells) (Fig. 8) are unaltered in p53-deficient cells, including IM-9 with p53 knockdown by siRNA (unpublished data), and therefore, a lack of requirement for caspase-2 is not surprising.
Recently, based on genetic data, it has also been reported that an amplification loop involving mitochondria is required to trigger massive cytochrome c release from mitochondria into the cytosol and abundant effector caspase-3 and/or caspase-7 activation, leading to cell death (26). Consistent with our model, Bax translocation to the mitochondria and cytochrome c release were impaired in cells deficient in effector caspase-3 and -7, indicating that caspases regulate mitochondrial events. This is consistent with a recent account of the mechanism of the cytochrome c role in apoptosis that clearly documents its biphasic release in the cytosol in multiple biologically relevant situations (15).
While p18-cyclin E activates an apoptosis pathway that is dependent on Bax and Ku70, it is possible that p18-cyclin E may also regulate cell death to some extent by a Bax- and/or Ku70-independent pathway. Indeed, neither Bax nor Ku70 deficiency in knockout MEFs nor siRNA-mediated silencing of Bax in IM-9 completely abolished cell death, suggesting a Bax- and/or Ku70-independent apoptosis component induced by p18-cyclin E. Moreover, Ku70 or Ku70(1-535) does not prevent the cell death mediated by p18-cyclin E completely either, indicating the presence of Ku70-independent cell death. Most importantly, once Bax is activated by p18-cyclin E or other stimuli (4, 44), leading to its translocation to mitochondria, the activation cannot be reversed by Ku70(496-609), even though the 496 to 609 amino acid residues of Ku70 bind to the endogenous inactive Bax in the cytosol. This result suggests that a Bax-independent cell death pathway is also present in this system in addition to the predominant Bax-dependent apoptosis.
In conclusion, we have identified p18-cyclin E, Ku70, and Bax as key regulators of the intrinsic apoptotic pathway execution. So far, we have found that cyclin E cleavage is limited to human hematopoietic tumor cells, with their sensitivity to genotoxic stress accounted for by their abilities to generate p18-cyclin E. In cells with functional Ku70 proteins, p18-cyclin E induces the dissociation of Bax from Ku70, which is followed by Bax activation and apoptosis. Moreover, p18-cyclin E-mediated Bax dissociation from Ku70 enhances radiation-induced cell death. p18-cyclin E may thus provide a critical physiological balance between the two key cellular responses to DNA damage (cell cycle control and apoptosis) (13) that, when perturbed, facilitate cancer. Future experiments will determine whether p18-cyclin E binding to Ku70 also impacts the third key cellular response to repair the DNA damage caused by genotoxic stress. Cyclin E expression is increased in several human carcinomas, including those of hematopoietic origin. Our findings suggest that cyclin E-derived fragments, such as p18-cyclin E or smaller derivatives, may become effective therapeutics for the treatment of hematopoietic malignancies.
| ACKNOWLEDGMENTS |
|---|
This work was supported by research grants from the U.S. National Institutes of Health (CA82858 and CA81504).
| FOOTNOTES |
|---|
Published ahead of print on 26 February 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Chen, Q., Y. C. Chai, S. Mazumder, C. Jiang, R. M. Macklis, G. M. Chisolm, and A. Almasan. 2003. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ. 10:323-334.[CrossRef][Medline]
3. Chen, Q., B. Gong, and A. Almasan. 2000. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ. 7:227-233.[CrossRef][Medline]
4. Cohen, H. Y., S. Lavu, K. J. Bitterman, B. Hekking, T. A. Imahiyerobo, C. Miller, R. Frye, H. Ploegh, B. M. Kessler, and D. A. Sinclair. 2004. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13:627-638.[CrossRef][Medline]
5. Cory, S., D. C. Huang, and J. M. Adams. 2003. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590-8607.[CrossRef][Medline]
6. Danial, N. N., and S. J. Korsmeyer. 2004. Cell death: critical control points. Cell 116:205-219.[CrossRef][Medline]
7. Dansen, T. B., J. Whitfield, F. Rostker, L. Brown-Swigart, and G. I. Evan. 2006. Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J. Biol. Chem. 281:10890-10895.
8. Deckwerth, T. L., J. L. Elliott, C. M. Knudson, E. M. Johnson, Jr., W. D. Snider, and S. J. Korsmeyer. 1996. BAX is required for neuronal death after trophic factor deprivation and during development. Neuron 17:401-411.[CrossRef][Medline]
9. De Maria, R., A. Zeuner, A. Eramo, C. Domenichelli, D. Bonci, F. Grignani, S. M. Srinivasula, E. S. Alnemri, U. Testa, and C. Peschle. 1999. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 401:489-493.[CrossRef][Medline]
10. Dlugosz, P. J., L. P. Billen, M. G. Annis, W. Zhu, Z. Zhang, J. Lin, B. Leber, and D. W. Andrews. 2006. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J. 25:2287-2296.[CrossRef][Medline]
11. Duli
, V., E. Lees, and S. I. Reed. 1992. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958-1961.
12. Elledge, S. J. 1996. Cell cycle checkpoints: preventing an identity crisis. Science 274:1664-1672.
13. Evan, G. I., and K. H. Vousden. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-348.[CrossRef][Medline]
14. Fewell, J. W., and E. L. Kuff. 1996. Intracellular redistribution of Ku immunoreactivity in response to cell-cell contact and growth modulating components in the medium. J. Cell Sci. 109:1937-1946.[Abstract]
15. Garrido, C., L. Galluzzi, M. Brunet, P. E. Puig, C. Didelot, and G. Kroemer. 2006. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 13:1423-1433.[CrossRef][Medline]
16. Geng, Y., Q. Yu, E. Sicinska, M. Das, J. E. Schneider, S. Bhattacharya, W. M. Rideout, R. T. Bronson, H. Gardner, and P. Sicinski. 2003. Cyclin E ablation in the mouse. Cell 114:431-443.[CrossRef][Medline]
17. Gong, B., Q. Chen, B. Endlich, S. Mazumder, and A. Almasan. 1999. Ionizing radiation-induced, Bax-mediated cell death is dependent on activation of cysteine and serine proteases. Cell Growth Differ. 10:491-502.
18. Gu, Y., S. Jin, Y. Gao, D. T. Weaver, and F. W. Alt. 1997. Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc. Natl. Acad. Sci. USA 94:8076-8081.
19. Guo, B., D. Zhai, E. Cabezas, K. Welsh, S. Nouraini, A. C. Satterthwait, and J. C. Reed. 2003. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423:456-461.[CrossRef][Medline]
20. Hetz, C., P. Bernasconi, J. Fisher, A. H. Lee, M. C. Bassik, B. Antonsson, G. S. Brandt, N. N. Iwakoshi, A. Schinzel, L. H. Glimcher, and S. J. Korsmeyer. 2006. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1
. Science 312:572-576.
21. Huang, H., K. M. Regan, Z. Lou, J. Chen, and D. J. Tindall. 2006. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314:294-297.
22. Jackson, P. K., S. Chevalier, M. Philippe, and M. W. Kirschner. 1995. Early events in DNA replication require cyclin E and are blocked by p21CIP1. J. Cell Biol. 130:755-769.
23. Jin, S., and D. T. Weaver. 1997. Double-strand break repair by Ku70 requires heterodimerization with Ku80 and DNA binding functions. EMBO J. 16:6874-6885.[CrossRef][Medline]
24. Kepp, O., K. Rajalingam, S. Kimmig, and T. Rudel. 2007. Bak and Bax are non-redundant during infection- and DNA damage-induced apoptosis. EMBO J. 26:825-834.[CrossRef][Medline]
25. Koff, A., A. Giordano, D. Desai, K. Yamashita, J. W. Harper, S. Elledge, T. Nishimoto, D. O. Morgan, B. R. Franza, and J. M. Roberts. 1992. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689-1694.
26. Lakhani, S. A., A. Masud, K. Kuida, G. A. Porter, Jr., C. J. Booth, W. Z. Mehal, I. Inayat, and R. A. Flavell. 2006. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311:847-851.
27. Launay, S., O. Hermine, M. Fontenay, G. Kroemer, E. Solary, and C. Garrido. 2005. Vital functions for lethal caspases. Oncogene 24:5137-5148.[CrossRef][Medline]
28. Li, G. C., F. He, X. Shao, M. Urano, L. Shen, D. Kim, M. Borrelli, S. A. Leibel, P. H. Gutin, and C. C. Ling. 2003. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res. 63:3268-3274.
29. Lieber, M. R., Y. Ma, U. Pannicke, and K. Schwarz. 2003. Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell Biol. 4:712-720.[CrossRef][Medline]
30. Mazumder, S., Q. Chen, B. Gong, J. A. Drazba, J. C. Buchsbaum, and A. Almasan. 2002. Proteolytic cleavage of cyclin E leads to inactivation of associated kinase activity and amplification of apoptosis in hematopoietic cells. Mol. Cell. Biol. 22:2398-2409.
31. Mazumder, S., E. L. DuPree, and A. Almasan. 2004. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr. Cancer Drug Targets 4:65-75.[CrossRef][Medline]
32. Mazumder, S., B. Gong, and A. Almasan. 2000. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells. Oncogene 19:2828-2835.[CrossRef][Medline]
33. Murray, A. W. 2004. Recycling the cell cycle: cyclins revisited. Cell 116:221-234.[CrossRef][Medline]
34. Newmeyer, D. D., and S. Ferguson-Miller. 2003. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112:481-490.[CrossRef][Medline]
35. Nishizaki, M., R. E. Meyn, L. B. Levy, E. N. Atkinson, R. A. White, J. A. Roth, and L. Ji. 2001. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin. Cancer Res. 7:2887-2897.
36. Ohtsubo, M., A. M. Theodoras, J. Schumacher, J. M. Roberts, and M. Pagano. 1995. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 15:2612-2624.[Abstract]
37. Perez, G. I., R. Robles, C. M. Knudson, J. A. Flaws, S. J. Korsmeyer, and J. L. Tilly. 1999. Prolongation of ovarian lifespan into advanced chronological age by Bax deficiency. Nat. Genet. 21:200-203.[CrossRef][Medline]
38. Ray, S., and A. Almasan. 2003. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63:4713-4723.
39. Reed, S. I. 2003. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat. Rev. Mol. Cell Biol. 4:855-864.[CrossRef][Medline]
40. Resnitzky, D., and S. I. Reed. 1995. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol. Cell. Biol. 15:3463-3469.[Abstract]
42. Schinzel, A., T. Kaufmann, and C. Borner. 2004. Bcl-2 family members: integrators of survival and death signals in physiology and pathology. Biochim. Biophys. Acta 1644:95-105.[Medline]
43. Sharpe, J. C., D. Arnoult, and R. J. Youle. 2004. Control of mitochondrial permeability by Bcl-2 family members. Biochim. Biophys. Acta 1644:107-113.[Medline]
44. Subramanian, C., A. W. Opipari, Jr., X. Bian, V. P. Castle, and R. P. Kwok. 2005. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102:4842-4847.
45. Tinel, A., and J. Tschopp. 2004. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304:843-846.
46. Vakifahmetoglu, H., M. Olsson, S. Orrenius, and B. Zhivotovsky. 2006. Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene 25:5683-5692.[CrossRef][Medline]
47. Wei, M. C., W. X. Zong, E. H. Cheng, T. Lindsten, V. Panoutsakopoulou, A. J. Ross, K. A. Roth, G. R. MacGregor, C. B. Thompson, and S. J. Korsmeyer. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292:727-730.
48. Wolter, K. G., Y. T. Hsu, C. L. Smith, A. Nechushtan, X. G. Xi, and R. J. Youle. 1997. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139:1281-1292.
49. Yang, C. R., S. Yeh, K. Leskov, E. Odegaard, H. L. Hsu, C. Chang, T. J. Kinsella, D. J. Chen, and D. A. Boothman. 1999. Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res. 27:2165-2174.
50. Zeuner, A., A. Eramo, U. Testa, N. Felli, E. Pelosi, G. Mariani, S. M. Srinivasula, E. S. Alnemri, G. Condorelli, C. Peschle, and R. De Maria. 2003. Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death Differ. 10:905-913.[CrossRef][Medline]
51. Zhai, D., F. Luciano, X. Zhu, B. Guo, A. C. Satterthwait, and J. C. Reed. 2005. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J. Biol. Chem. 280:15815-15824.
52. Zong, W. X., T. Lindsten, A. J. Ross, G. R. MacGregor, and C. B. Thompson. 2001. BH3-only proteins that bind prosurvival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 15:1481-1486.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||